mAbxience |
PAHO selects centers in Argentina, Brazil to develop COVID-19 mRNA vaccines
09/22/2021
Washington DC, September 21, 2021 (PAHO) – The Pan American Health Organization (PAHO) has announced the selection of two centers in Argentina and Brazil as regional hubs for the development and production of mRNA-based vaccines in Latin America in a bid to tackle COVID-19 and future infectious-disease challenges. The Bio-Manguinhos Institute of Technology on Immunobiologicals […]
Insud Pharma secures “Excellent” rating in the Profarma programme
05/05/2021
It is a recognition of the brands of the group Chemo, Exeltis and mAbxience for their commitment to industrial development and investment in our country It is the second consecutive year that the group has received this rating from the Ministry of Industry The Spanish pharmaceutical group Insud Pharma and its brands Chemo, Exeltis and […]
European Commission Approves mAbxience’s Bevacizumab For The Treatment Of Certain Types Of Cancer
03/31/2021
The European Commission (EC) has approved mAbxience’s MB02 biosimilar to Avastin® (Bevacizumab), in Europe.
Spain’s mAbxience boosting biologics capacity with 4,000 L SUB
03/25/2021
Biosimilar maker and CDMO mAbxience will install an ABEC 4,000 L CSR bioreactor at its site in León, Spain. mAbxience, the biologics division of Spain’s Insud Pharma group, claims its León plant is “the biggest biologic plant in Spain and the first in Europe with fully integrated single-use technology in most processes.” Now the site […]
ESMO publication: EMA grants a marketing authorisation for two biosimilar medicines, bevacizumab
02/15/2021
They received a positive opinion for the treatment of carcinoma of the colon or rectum, breast cancer, NSCLC, RCC, epithelial ovarian cancer, and carcinoma of the cervix